Cargando…

Serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma

BACKGROUND: Exfoliative glaucoma (XFG) is typically classified as a high-pressure type of secondary open-angle glaucoma that develops as a consequence of exfoliation syndrome (XFS). Exfoliation syndrome is an age-related, generalized disorder of the extracellular matrix characterized by production a...

Descripción completa

Detalles Bibliográficos
Autores principales: Maric, Vesna D., Bozic, Marija M., Cirkovic, Andja M., Stankovic, Sanja Dj, Marjanovic, Ivan S., Grgurevic, Anita D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535222/
https://www.ncbi.nlm.nih.gov/pubmed/31198625
http://dx.doi.org/10.7717/peerj.6920
_version_ 1783421560452808704
author Maric, Vesna D.
Bozic, Marija M.
Cirkovic, Andja M.
Stankovic, Sanja Dj
Marjanovic, Ivan S.
Grgurevic, Anita D.
author_facet Maric, Vesna D.
Bozic, Marija M.
Cirkovic, Andja M.
Stankovic, Sanja Dj
Marjanovic, Ivan S.
Grgurevic, Anita D.
author_sort Maric, Vesna D.
collection PubMed
description BACKGROUND: Exfoliative glaucoma (XFG) is typically classified as a high-pressure type of secondary open-angle glaucoma that develops as a consequence of exfoliation syndrome (XFS). Exfoliation syndrome is an age-related, generalized disorder of the extracellular matrix characterized by production and progressive accumulation of a fibrillar exfoliation material (XFM) in intra- and extraocular tissues. Exfoliation material represents complex glycoprotein/proteoglycan structure composed of a protein core surrounded by glycosaminoglycans such as heparan sulfate (HS) and chondroitin sulfate (CS). The purpose of the present study was to investigate HS and CS concentrations in serum samples of patients with newly diagnosed XFG and compare the obtained values with those pertaining to newly diagnosed primary open-angle glaucoma (POAG), normal controls (NC) and subjects with XFS. METHODS: This case–control study involved 165 subjects, including patients with newly diagnosed XFG, patients with newly diagnosed POAG, subjects with XFS and age- and sex-matched NC. The study was conducted at the Glaucoma Department of Clinic for Eye Diseases, Clinical Centre of Serbia, as the referral center for glaucoma in Serbia. RESULTS: The mean age in the XFG, POAG, XFS and NC groups was 73.3 ± 9.0, 66.3 ± 7.8, 75.5 ± 7.0 and 73.5 ± 9.5 years, respectively, XFG vs. POAG, p < 0.001. Mean serum HS concentrations in the XFG, POAG, NC and XFS groups were 3,189.0 ± 1,473.8 ng/mL, 2,091.5 ± 940.9 ng/mL, 2,543.1 ± 1,397.3 ng/mL and 2,658.2 ± 1,426.8 ng/mL respectively, XFG vs. POAG, p = 0.001 and XFG vs. NC, p = 0.032. Mean serum CS concentrations in the XFG, POAG, NC and XFS group were 43.9 ± 20.7 ng/mL, 38.5 ± 22.0 ng/mL, 35.8 ± 16.4 ng/mL and 43.3 ± 21.8 ng/mL, respectively, XFG vs. NC, p = 0.041. CONCLUSIONS: Our findings revealed greater HS and CS concentrations in XFG patients and XFS subjects compared to those without XFM. Implications of HS and CS in the pathophysiology of XFS and glaucoma should be studied further. Serum is easily accessible and should thus be explored as rich sources of potential biomarkers. Further research should aim to identify XFG biomarkers that could be utilized in routine blood analysis tests, aiding in timely disease diagnosis.
format Online
Article
Text
id pubmed-6535222
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-65352222019-06-13 Serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma Maric, Vesna D. Bozic, Marija M. Cirkovic, Andja M. Stankovic, Sanja Dj Marjanovic, Ivan S. Grgurevic, Anita D. PeerJ Clinical Trials BACKGROUND: Exfoliative glaucoma (XFG) is typically classified as a high-pressure type of secondary open-angle glaucoma that develops as a consequence of exfoliation syndrome (XFS). Exfoliation syndrome is an age-related, generalized disorder of the extracellular matrix characterized by production and progressive accumulation of a fibrillar exfoliation material (XFM) in intra- and extraocular tissues. Exfoliation material represents complex glycoprotein/proteoglycan structure composed of a protein core surrounded by glycosaminoglycans such as heparan sulfate (HS) and chondroitin sulfate (CS). The purpose of the present study was to investigate HS and CS concentrations in serum samples of patients with newly diagnosed XFG and compare the obtained values with those pertaining to newly diagnosed primary open-angle glaucoma (POAG), normal controls (NC) and subjects with XFS. METHODS: This case–control study involved 165 subjects, including patients with newly diagnosed XFG, patients with newly diagnosed POAG, subjects with XFS and age- and sex-matched NC. The study was conducted at the Glaucoma Department of Clinic for Eye Diseases, Clinical Centre of Serbia, as the referral center for glaucoma in Serbia. RESULTS: The mean age in the XFG, POAG, XFS and NC groups was 73.3 ± 9.0, 66.3 ± 7.8, 75.5 ± 7.0 and 73.5 ± 9.5 years, respectively, XFG vs. POAG, p < 0.001. Mean serum HS concentrations in the XFG, POAG, NC and XFS groups were 3,189.0 ± 1,473.8 ng/mL, 2,091.5 ± 940.9 ng/mL, 2,543.1 ± 1,397.3 ng/mL and 2,658.2 ± 1,426.8 ng/mL respectively, XFG vs. POAG, p = 0.001 and XFG vs. NC, p = 0.032. Mean serum CS concentrations in the XFG, POAG, NC and XFS group were 43.9 ± 20.7 ng/mL, 38.5 ± 22.0 ng/mL, 35.8 ± 16.4 ng/mL and 43.3 ± 21.8 ng/mL, respectively, XFG vs. NC, p = 0.041. CONCLUSIONS: Our findings revealed greater HS and CS concentrations in XFG patients and XFS subjects compared to those without XFM. Implications of HS and CS in the pathophysiology of XFS and glaucoma should be studied further. Serum is easily accessible and should thus be explored as rich sources of potential biomarkers. Further research should aim to identify XFG biomarkers that could be utilized in routine blood analysis tests, aiding in timely disease diagnosis. PeerJ Inc. 2019-05-23 /pmc/articles/PMC6535222/ /pubmed/31198625 http://dx.doi.org/10.7717/peerj.6920 Text en © 2019 Maric et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Clinical Trials
Maric, Vesna D.
Bozic, Marija M.
Cirkovic, Andja M.
Stankovic, Sanja Dj
Marjanovic, Ivan S.
Grgurevic, Anita D.
Serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma
title Serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma
title_full Serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma
title_fullStr Serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma
title_full_unstemmed Serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma
title_short Serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma
title_sort serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma
topic Clinical Trials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535222/
https://www.ncbi.nlm.nih.gov/pubmed/31198625
http://dx.doi.org/10.7717/peerj.6920
work_keys_str_mv AT maricvesnad serumheparansulfateandchondroitinsulfateconcentrationsinpatientswithnewlydiagnosedexfoliativeglaucoma
AT bozicmarijam serumheparansulfateandchondroitinsulfateconcentrationsinpatientswithnewlydiagnosedexfoliativeglaucoma
AT cirkovicandjam serumheparansulfateandchondroitinsulfateconcentrationsinpatientswithnewlydiagnosedexfoliativeglaucoma
AT stankovicsanjadj serumheparansulfateandchondroitinsulfateconcentrationsinpatientswithnewlydiagnosedexfoliativeglaucoma
AT marjanovicivans serumheparansulfateandchondroitinsulfateconcentrationsinpatientswithnewlydiagnosedexfoliativeglaucoma
AT grgurevicanitad serumheparansulfateandchondroitinsulfateconcentrationsinpatientswithnewlydiagnosedexfoliativeglaucoma